Organogenesis Holdings Inc. announced plans to expand its manufacturing capacity by securing a long-term lease for a 122,000-square-foot biomanufacturing facility in Smithfield, Rhode Island. This strategic investment is designed to support the company's future growth initiatives.
The new facility will be instrumental in the planned reintroduction of Dermagraft, with sales expected to resume by the second half of 2027, and TransCyte, a PMA-approved bioengineered cellular tissue scaffold for severe burns. It will also facilitate the introduction of FortiShield, a biosynthetic transitional wound matrix.
This expansion is projected to further enhance Organogenesis's long-term growth and margin profile by increasing production capabilities for its industry-leading portfolio. The lease is contingent upon anticipated state and local tax incentives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.